Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

R C Donehower

Showing results (41-50 of 129) with videos related to

Pageof 13
Sort By:
Journal of Cancer Research and Clinical Oncology|January 1, 1993
Sequence-dependent cytotoxic effects due to combinations of cisplatin and the antimicrotubule agents taxol and vincristineE K Rowinsky, M J Citardi, D A Noe, et al.
Journal of the National Cancer Institute|February 17, 1993
The current status of camptothecin analogues as antitumor agentsW J Slichenmyer, E K Rowinsky, R C Donehower, et al.
Cancer Research|November 1, 1984
Direct relationship of marrow cell growth and 1-beta-D-arabinofuranosylcytosine metabolismJ E Karp, R C Donehower, G B Dole, et al.
Cancer Chemotherapy and Pharmacology|January 1, 1989
A phase I trial of trimetrexate glucuronate (NSC 352122) given every 3 weeks: clinical pharmacology and pharmacodynamicsL B Grochow, D A Noe, D S Ettinger, et al.
Cancer Research|February 1, 1990
Development of polyploidization in taxol-resistant human leukemia cells in vitroJ R Roberts, D C Allison, R C Donehower, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|July 26, 2003
Phase II study of flavopiridol in patients with advanced colorectal cancerM Aklilu, H L Kindler, R C Donehower, et al.
Cancer Surveys|January 1, 1993
Taxol: pharmacology, metabolism and clinical implicationsE K Rowinsky, M Wright, B Monsarrat, et al.
Anti-Cancer Drugs|June 1, 1996
A phase II trial of topotecan in patients with previously untreated pancreatic cancerS O'Reilly, R C Donehower, E K Rowinsky, et al.
Journal of the National Cancer Institute|February 1, 1982
Phase I-phase II trial of N-phosphonacetyl-L-aspartic acid given by intravenous infusion and 5-fluorouracil given by bolus injectionC Erlichman, R C Donehower, J L Speyer, et al.
Seminars in Oncology|August 1, 1993
Clinical toxicities encountered with paclitaxel (Taxol)E K Rowinsky, E A Eisenhauer, V Chaudhry, et al.
Pageof 13

Showing results (41-50 of 129) with videos related to

Sort By:
Pageof 13
Journal of Cancer Research and Clinical Oncology|January 1, 1993
Sequence-dependent cytotoxic effects due to combinations of cisplatin and the antimicrotubule agents taxol and vincristineE K Rowinsky, M J Citardi, D A Noe, et al.
Journal of the National Cancer Institute|February 17, 1993
The current status of camptothecin analogues as antitumor agentsW J Slichenmyer, E K Rowinsky, R C Donehower, et al.
Cancer Research|November 1, 1984
Direct relationship of marrow cell growth and 1-beta-D-arabinofuranosylcytosine metabolismJ E Karp, R C Donehower, G B Dole, et al.
Cancer Chemotherapy and Pharmacology|January 1, 1989
A phase I trial of trimetrexate glucuronate (NSC 352122) given every 3 weeks: clinical pharmacology and pharmacodynamicsL B Grochow, D A Noe, D S Ettinger, et al.
Cancer Research|February 1, 1990
Development of polyploidization in taxol-resistant human leukemia cells in vitroJ R Roberts, D C Allison, R C Donehower, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|July 26, 2003
Phase II study of flavopiridol in patients with advanced colorectal cancerM Aklilu, H L Kindler, R C Donehower, et al.
Cancer Surveys|January 1, 1993
Taxol: pharmacology, metabolism and clinical implicationsE K Rowinsky, M Wright, B Monsarrat, et al.
Anti-Cancer Drugs|June 1, 1996
A phase II trial of topotecan in patients with previously untreated pancreatic cancerS O'Reilly, R C Donehower, E K Rowinsky, et al.
Journal of the National Cancer Institute|February 1, 1982
Phase I-phase II trial of N-phosphonacetyl-L-aspartic acid given by intravenous infusion and 5-fluorouracil given by bolus injectionC Erlichman, R C Donehower, J L Speyer, et al.
Seminars in Oncology|August 1, 1993
Clinical toxicities encountered with paclitaxel (Taxol)E K Rowinsky, E A Eisenhauer, V Chaudhry, et al.
Pageof 13